NCT04671251已完成1 期
A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 6
- 主要终点
- Recommended Phase 2 Dose
研究概览
简要总结
This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma.
The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.
详细描述
This was a multicenter, open-label, dose-escalation, sequential groups Phase 1b clinical study in subjects with R/R multiple myeloma. The study utilized a "3+3" design. Three subjects were enrolled at each dose, starting with the initial dose of 4 mg/kg. If there were no DLTs, escalation to the next cohort took place. If there was 1 DLT, then the cohort was to be expanded to 6. If there were no further DLTs, then escalation to the next dose took place. If there were 2 DLTs in the initial 3 subjects, or 2 in the expanded cohort of 6 subjects, then the maximally tolerated dose (MTD) had been exceeded and dose escalation stopped. The dose prior to the dose where DLT was observed was then the RP2D. To allow safety assessment, the dosing of subjects within each dose level was staggered, with at least 24 hours between each subject.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has active R/R multiple myeloma.
- •Subject has measurable myeloma based on any of the following:
- •Serum M-protein > 0.5 g/dL
- •Urine M-protein > 200 mg/24 hours
- •Serum free light chains > 10 mg/dL
- •Measurable plasmacytoma or extramedullary disease
- •Subject has active myeloma despite prior therapy with a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.
- •Note: Subject must not be a candidate for regimens known to provide clinical benefit.
- •Subject has an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or
- •Subject is > 18 years of age.
- •Subject has adequate hematopoietic, renal and hepatic function, defined as:
- •Absolute neutrophil count > 1,000/μL; platelet count > 75,000/μL in patients with < 50% marrow involvement
- •Absolute neutrophil count > 750/μL; platelet count > 50,000/μL in patients with >50% marrow involvement
- •Serum creatinine < 2.5 mg/dL or calculated creatinine clearance of > 30 mL/min according to the Cockcroft-Gault equation
- •Aspartate transaminase/alanine transaminase ≤2.5× the upper limit of normal (ULN) and total bilirubin < 2× the ULN
- •If applicable, the subject has undergone prior autologous hematopoietic stem cell transplantation more than 100 days prior to the Screening Visit.
- •Female patients of childbearing potential who are heterosexually active and male patients with female sexual partners of childbearing potential must agree to use an effective method of contraception (eg, oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device) or abstain from sexual activity during the study and for 220 days (5 half-lives) following the last dose of study medication, or to abstain from sexual intercourse for this duration of study participation. A woman not of childbearing potential is one who has undergone bilateral oophorectomies or who is post-menopausal, defined as the absence of menstrual periods for 12 consecutive months.
- •Subject has provided written informed consent for this study.
排除标准
- •Subject has currently active infection requiring use of systemic antimicrobial therapy.
- •Subject has received corticosteroids (>10 mg/daily prednisone or equivalent) or chemotherapy within 2 weeks of study drugs (4 weeks for nitrosourea, melphalan or monoclonal antibodies).
- •Subject has hyperviscosity syndrome.
- •Subject has central nervous system involvement by myeloma, including leptomeningeal involvement.
- •Subject is judged to be at risk for impending fracture.
- •Subject has known amyloidosis or POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes) syndrome.
- •Subject had another malignancy within 1 year of study entry with high probability of recurrence.
- •Subject is pregnant or lactating.
- •Subject has a history of, or tests positive for, hepatitis B, untreated hepatitis C or human immunodeficiency virus (HIV). Subject with hepatitis C who has received a full course of anti-viral therapy or who is currently receiving anti-viral therapy with undetectable levels of hepatitis C RNA is eligible for the trial.
- •Subject has undergone major surgery or trauma within 4 weeks of study entry.
- •Subject has been previously treated with an anti IL 18 antibody.
- •Subject is currently taking immunomodulatory drugs, including pharmacologic doses of systemic glucocorticoids (> 10 mg prednisone daily or equivalent), anti tumor necrosis factor alpha (TNFα) antibodies, anti-IL-17 antibodies, anti IL 12/23 antibodies, phosphodiesterase-4 (PDE-4) inhibitors, janus kinase (JAK) inhibitors, IL-6 inhibitors, rituximab, methotrexate, cyclosporine, mycophenolate.
- •Subject with known active autoimmune disorders including, but not limited to, rheumatoid arthritis, lupus, systemic sclerosis, Sjogren's syndrome, psoriatic arthritis, ulcerative colitis, Crohn's disease, vasculitis, multiple sclerosis. Subjects with autoimmune endocrinopathies on stable doses of replacement hormone therapy are eligible for the trial.
- •Subject has had a prior allogeneic transplant.
- •Subject has New York Heart Association (NYHA) Class III or IV Congestive Heart Failure (CHF), myocardial infarction or acute coronary syndrome within 6 months prior to the Screening Visit, ongoing angina pectoris, severe peripheral vascular disease, or any other concomitant medical disorder that might interfere with the subject's participation in the trial or interpretation of the study data.
- •Subject has psychiatric, substance abuse or social conditions that would interfere with the subject's participation or cooperation with the requirements of the trial.
- •Subject has known hypersensitivity to any of the components of AEVI-007.
研究组 & 干预措施
AEVI-007
Experimental
Open-label, dose-escalation, single-arm
干预措施: AEVI-007 (Drug)
结局指标
主要结局
Recommended Phase 2 Dose
时间窗: Cohorts 1-3 will take approximately 4-5 months
Identify the recommended Phase 2 dose based on safety, pharmacokinetics and pharmacodynamics observed in this Phase 1b study.
次要结局
- Apparent Terminal Half-Life of AEVI-007(Approximately 9 months)
- Progression Free Survival (PFS)(Approximately 9 months)
- Incidence of Treatment Emergent Adverse Events (TEAEs)(Approximately 9 months)
- Incidence of Clinically Significant Changes in Vital Signs(Approximately 9 months)
- Incidence of Clinically Significant Changes to Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score(Approximately 9 months)
- Maximum Observed Concentration of AEVI-007(Approximately 9 months)
- Incidence of Clinically Significant Changes in Clinical Laboratory Results(Approximately 9 months)
- Incidence of Clinically Significant Changes in Physical Examination Findings(Approximately 9 months)
- Clearance of AEVI-007(Approximately 9 months)
- Anti-myeloma activity(Approximately 9 months)
- Determination of ADAs(Approximately 9 months)
- Incidence of Clinically Significant Changes in Electrocardiogram Recordings(Approximately 9 months)
- Volume of Distribution of AEVI-007(Approximately 9 months)
- Area Under the Concentration-Time Curve From Time 0 to Time t of AEVI-007(Approximately 9 months)
- Time to Response (TTR)(Approximately 9 months)
- Duration of Response(Approximately 9 months)
研究者
研究点 (6)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsMetastatic Solid TumorAdvanced or Metastatic Solid TumorNCT06270706Pliant Therapeutics, Inc.124
招募中
1 期
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung CancerAdvanced Solid TumoursSmall Cell Lung CancerNCT04434482Impact Therapeutics, Inc.113
招募中
1 期
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyAdvanced CancerAdvanced Solid TumorMetastasisMSI-HighMismatch Repair DeficiencyMelanomaPleural MesotheliomaHepatocellular CancerRenal Cell CancerKidney CancerNon Small Cell Lung CancerAnaplastic Lymphoma Kinase Genomic Tumor AberrationsALK Genomic Tumor AberrationsSkin CancerColorectal CancerHepatocellular CarcinomaRenal Cell CarcinomaNSCLCNCT063623697 Hills Pharma, LLC126
已完成
1 期
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901Pancreatic CancerNCT04805307Keymed Biosciences Co.Ltd176
已完成
1 期
A Study of CS1002 in Subjects With Advanced Solid TumorsSolid Tumor, AdultNCT03523819CStone Pharmaceuticals91